Autism Clinical Trial
Official title:
Cholesterol in Autism Spectrum Disorder (ASD): Characterization and Treatment
Background:
- Autism spectrum disorders (ASD) are developmental disabilities characterized by impaired
social interaction and repetitive and/or stereotypical behaviors. Research studies suggest
that some individuals with ASD have very low blood cholesterol levels. This low cholesterol
level and other abnormal sterol levels may be important markers for
subtypes of ASD. Providing additional cholesterol to the diets of children with ASD may help
improve behavior.
- These findings will guide the medical community in identifying individuals who should be
tested for sterol disorders. This study will also help researchers learn whether adding extra
cholesterol to the diet will improve behavioral and other autism spectrum characteristics
seen in individuals with ASD and low cholesterol.
Objectives:
- To determine cholesterol levels in children with autism spectrum disorders.
- To compare behavioral and other characteristics among children who have autism spectrum
disorders and high, low, or normal cholesterol levels.
- To determine whether adding cholesterol to the diet will improve behavioral and other
characteristics in individuals with ASD and low cholesterol.
Eligibility:
- Children between the ages of 4 and 12 who have been diagnosed with an autism spectrum
disorder.
Design:
- Initial screening study will involve a collection of blood samples (for study purposes
and cholesterol testing).
- Children who have low cholesterol levels will take part in a study in which they will
receive either cholesterol supplementation or a placebo, and will have detailed physical
and psychological examinations to measure possible improvement in behavioral or other
characteristics.
- Children who have high or normal cholesterol levels will have further blood samples
taken, and will undergo an additional set of examinations for comparison purposes.
- Researchers may request blood or DNA samples from other family members (parents or
siblings), which will be collected through blood draws and cheek swabs.
Pilot work suggests that some individuals with autism spectrum disorders (ASD) have very low
blood cholesterol levels. This low cholesterol level and other abnormal sterol levels may be
important markers for subtypes of ASD. The proposed trial aims to characterize any clinical
differences between low-cholesterol ASD and normal-or-high-cholesterol ASD and to test the
response of individuals with ASD and low cholesterol to increased cholesterol in the diet.
Evidence for the role of low cholesterol in causing ASD in a subgroup of individuals comes
from five sources. First, half of individuals with Smith-Lemli-Opitz syndrome (SLOS) meet the
behavioral criteria for autistic disorder (Tierney et al, 2001), and three quarters have some
type of ASD (Sikora et al, 2006). Second, in individuals with SLOS, the lower the cholesterol
was in the blood and cerebrospinal fluid, the more severe were the autism and IQ and adaptive
function deficits. Third, in SLOS, improvement was found in social and communication
abilities with added dietary cholesterol. Fourth, cholesterol was low in a pilot study of 100
children with autism of unknown cause (Tierney et al, 2006). Fifth, it is becoming
increasingly clear that cholesterol plays a pivotal role in several aspects of brain
development.
This proposal is designed to 1) determine the prevalence of hypocholesterolemia in ASD
individuals (ASD+Hypo); 2) determine the prevalence of hypercholesterolemia (in ASD
individuals (ASD+Hyper); 3) determine the rate of SLOS in the ASD subjects; 4) determine the
phenotype (physical, behavioral, and developmental) at less than the 5th centile (ASD+Hypo)
and greater than the 95th centile (ASD+Hyper) individuals and normal cholesterol (ASD+Normal)
in the ASD subjects; 5) test the efficacy of dietary cholesterol supplementation in ASD
individuals with hypocholesterolemia; 6) determine whether a raised dose of cholesterol
supplementation is more effective than a lower dose; and 7) create a repository of
biomaterial samples from individuals with ASD and their biological family members.
Three sites (Kennedy Krieger Institute [KKI], Ohio State University [OSU], and the National
Institutes of Health [NIH]) will collaborate to accomplish the objectives of this study. In
addition to defining the frequency of altered cholesterol homeostasis in ASD, 60 youths (20
at each site) with ASD plus hypocholesterolemia will enter a 12-week, double-blind,
placebo-controlled trial immediately followed by a 12-week open-label cholesterol trial to
test the efficacy of dietary cholesterol supplementation. Outcome measures will include
standard tests of behavior, communication, and other autism features.
These findings will guide the medical community in identifying individuals who should be
tested for sterol disorders. This study will also help researchers learn whether adding extra
cholesterol to the diet will improve behavioral and other autism spectrum characteristics
seen in individuals with ASD and low cholesterol. The results of this study may help
individuals with hypocholesterolemic ASD by the knowledge of the therapeutic value and safety
of the use of cholesterol supplementation both biochemically and behaviorally. If improvement
is demonstrated, it opens a new window to understanding the neurologic mechanisms of ASD.
This knowledge may also be helpful for hypocholesterolemic individuals with ASD in that this
newly identified population will benefit from such supplementation. Even if cholesterol
supplementation is found to not be effective, important behavioral phenotype and
developmental information will be obtained that might be useful in identifying subjects with
ASD plus cholesterol abnormalities.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05302167 -
Molehill Mountain Feasibility Study.
|
N/A | |
Completed |
NCT04167839 -
Effects of Sensory Diets on Children's Sensory Processing Skills, Psychosocial Skills, and Classroom Engagement
|
N/A | |
Terminated |
NCT04049981 -
Investigation of Mechanisms of Action in Superpower Glass
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT06080087 -
Implementation Toolkit to Enhance EBP Among Marginalized Families
|
N/A | |
Recruiting |
NCT04107064 -
Achieving Steady Work Among Adults With Autism Through Specialized Employment Program
|
N/A | |
Completed |
NCT03206996 -
Exposure Therapy for Auditory Sensitivity in Autism
|
N/A | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Completed |
NCT05588570 -
Coaching Children With Anxiety and Autism Through Telehealth
|
N/A | |
Enrolling by invitation |
NCT06058104 -
Evaluating Efficacy of a Digital Game Therapeutic for Children With Autism
|
N/A | |
Completed |
NCT02911194 -
a2 Milk for Autism and Attention-deficit Hyperactivity Disorder (ADHD)
|
N/A | |
Completed |
NCT03002363 -
The Effects of Video Modeling of Audiological Testing on Pediatric Patient Compliance
|
Phase 1 | |
Withdrawn |
NCT02414451 -
Trial of Propranolol in Adults and Adolescents With ASD and Predictors of Response
|
N/A | |
Completed |
NCT02847182 -
Cord Blood Infusion for Children With Autism Spectrum Disorder
|
Phase 2 | |
Completed |
NCT02708290 -
Mental Imagery Therapy for Autism (MITA) - an Early Intervention Computerized Language Training Program for Children With ASD
|
||
Completed |
NCT02508922 -
Trial of Vitamin D3 Supplementation in Paediatric Autism
|
N/A | |
Completed |
NCT02536365 -
Sensory Integration Therapy in Autism: Mechanisms and Effectiveness
|
N/A | |
Completed |
NCT02720900 -
Prebiotic Intervention for Autism Spectrum Disorders
|
N/A | |
Recruiting |
NCT01836562 -
A Clinical Trial to Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Autism
|
Phase 1/Phase 2 | |
Recruiting |
NCT02255565 -
Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
|
Phase 4 | |
Completed |
NCT02154828 -
Clinical Evaluation of Integrative Practices Units Infant and Child Care for Unit Children With Typical or Atypical Autism (AUTISM)
|